Biotest AG and AERES Biomedical Successfully Complete Engineering of the Antibody BT-062

26-Jan-2005

In a collaborative research effort AERES Biomedical, Ltd. and Biotest AG successfully completed the engineering of the monoclonal antibody BT-062. The candidate is directed against a tumor-specific target expressed by multiple myeloma and is in development for this life-threatening tumour of the blood.

After BT-062 had shown impressive efficacy in an animal model of the disease, this is an important step towards the clinical development of the candidate. With tolerability and early efficacy displayed by BT-061 and BT-063 in patients with rheumatoid arthritis and systemic lupus erythematosus, respectively, BT-062 will be Biotest´s third monoclonal antibody entering clinical trials.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances